GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2011

J&J Engages Sanford-Burnham in Alzheimer Deal

  • Johnson & Johnson (J&J) is tapping into Sanford-Burnham for the discovery of compounds for Alzheimer disease and major psychiatric disorders. J&J, through its Ortho-McNeil-Janssen Pharmaceuticals division, gains exclusive access for a three-year term to a multidisciplinary team of scientists and Sanford-Burnham’s translational infrastructure.

    Sanford-Burnham will receive an up-front payment, yearly access fees, funding for discovery research, milestone payments, and royalties for successfully developed products. “Although we cannot disclose the financial terms of the agreement, I can tell you we believe the deal is bigger deal than the one recently announced by UCSF and Pfizer,” says Megan Lavine, a spokesperson for Sanford-Burnham.

    In November 2010, Pfizer set up the Global Centers for Therapeutic Innovation, which is to serve as a network of academic partnerships for drug R&D. The University of California, San Francisco was noted as the first participant, and The Wall Street Journal reported that Pfizer would pay up to $85 million over five years for access to UCSF discoveries.

    The J&J/Sanford-Burnham and Pfizer/UCSF deals are just two examples of pharmaceutical companies looking toward academic centers to feed their research pipelines. Sanford-Burnham’s first deal came in December 2010 when Takeda Pharmaceutical formed an alliance to discover and evaluate new therapeutic approaches to obesity. The two-year partnership aims to identify and validate obesity-related biomarkers and new peripheral molecular targets of mutual interest.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?